KR20210005245A - 만성 두드러기를 치료하기 위한 방법 및 조성물 - Google Patents

만성 두드러기를 치료하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20210005245A
KR20210005245A KR1020207034828A KR20207034828A KR20210005245A KR 20210005245 A KR20210005245 A KR 20210005245A KR 1020207034828 A KR1020207034828 A KR 1020207034828A KR 20207034828 A KR20207034828 A KR 20207034828A KR 20210005245 A KR20210005245 A KR 20210005245A
Authority
KR
South Korea
Prior art keywords
antibody
seq
amino acid
acid sequence
hvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207034828A
Other languages
English (en)
Korean (ko)
Inventor
크리스토퍼 로버트 베빙턴
네나드 토마세빅
헨릭 라스무쎈
Original Assignee
알라코스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알라코스 인크. filed Critical 알라코스 인크.
Publication of KR20210005245A publication Critical patent/KR20210005245A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020207034828A 2018-05-04 2019-05-03 만성 두드러기를 치료하기 위한 방법 및 조성물 Ceased KR20210005245A (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862667242P 2018-05-04 2018-05-04
US62/667,242 2018-05-04
US201962788719P 2019-01-04 2019-01-04
US62/788,719 2019-01-04
US201962797817P 2019-01-28 2019-01-28
US62/797,817 2019-01-28
US201962803211P 2019-02-08 2019-02-08
US62/803,211 2019-02-08
US201962806657P 2019-02-15 2019-02-15
US62/806,657 2019-02-15
PCT/US2019/030523 WO2019213468A1 (en) 2018-05-04 2019-05-03 Methods and compositions for treating chronic urticaria

Publications (1)

Publication Number Publication Date
KR20210005245A true KR20210005245A (ko) 2021-01-13

Family

ID=68386174

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207034828A Ceased KR20210005245A (ko) 2018-05-04 2019-05-03 만성 두드러기를 치료하기 위한 방법 및 조성물

Country Status (11)

Country Link
US (1) US20210246205A1 (https=)
EP (1) EP3788078A4 (https=)
JP (2) JP2021523117A (https=)
KR (1) KR20210005245A (https=)
CN (1) CN112384535A (https=)
AU (1) AU2019262167A1 (https=)
BR (1) BR112020022236A2 (https=)
CA (1) CA3099338A1 (https=)
MX (1) MX2020011377A (https=)
SG (1) SG11202010911WA (https=)
WO (1) WO2019213468A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200016232A (ko) 2017-05-05 2020-02-14 알라코스 인크. 알레르기성 안구 질환을 치료하기 위한 방법 및 조성물
JP2023541217A (ja) * 2020-07-10 2023-09-29 シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド 抗ＩｇＥ改変抗体及びその適用
KR102803012B1 (ko) * 2022-08-11 2025-04-30 오씨아이 주식회사 석유계 고연화점 피치의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201603127WA (en) * 2013-10-23 2016-05-30 Genentech Inc Methods of diagnosing and treating eosinophilic disorders
KR102311761B1 (ko) * 2013-12-09 2021-10-13 알라코스 인크. 항-Siglec-8 항체 및 그의 사용 방법
CA2939931C (en) * 2014-02-28 2025-04-22 Allakos Inc. METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SIGLEC8
US10604577B2 (en) * 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis

Also Published As

Publication number Publication date
MX2020011377A (es) 2020-11-24
JP2021523117A (ja) 2021-09-02
CN112384535A (zh) 2021-02-19
EP3788078A1 (en) 2021-03-10
BR112020022236A2 (pt) 2021-02-02
CA3099338A1 (en) 2019-11-07
US20210246205A1 (en) 2021-08-12
WO2019213468A1 (en) 2019-11-07
JP2024045612A (ja) 2024-04-02
EP3788078A4 (en) 2022-03-02
AU2019262167A1 (en) 2020-12-10
SG11202010911WA (en) 2020-12-30

Similar Documents

Publication Publication Date Title
JP6549143B2 (ja) 抗シグレック−８抗体およびその使用の方法
JP2017501744A5 (https=)
KR20200015511A (ko) 염증성 위장 장애를 치료하기 위한 방법 및 조성물
CN113747918A (zh) 治疗肥大细胞胃炎、肥大细胞食管炎、肥大细胞肠炎、肥大细胞十二指肠炎和/或肥大细胞胃肠炎的方法和组合物
JP2023086917A (ja) アレルギー性眼疾患を処置するための方法および組成物
JP2024045612A (ja) 慢性蕁麻疹を処置するための方法および組成物
US20220257758A1 (en) Methods of administering anti-siglec-8 antibodies and corticosteroids
US20190338027A1 (en) Methods and compositions for treating chronic obstructive pulmonary disorder
US20230406920A1 (en) Anti-siglec-8 antibody formulations
WO2022061032A1 (en) Methods and compositions for treating viral infection
WO2021081411A1 (en) Methods and compositions for treating irritable bowel syndrome and functional dyspepsia
WO2024043940A1 (en) Methods and compositions for treating atopic dermatitis
EA045206B1 (ru) Способы и композиции для лечения аллергических заболеваний глаз

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201203

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220502

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20250220

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250430

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D